At USCF, Walter began the work that might prove to be his
enduring legacy — the discovery of a key element in a
quality control mechanism that cells deploy to deal with stress
related to the buildup of misfolded proteins in the ER.
Advanced melanoma patients successfully treated with a combination of nivolumab and ipilimumab may
endure severe side effects, but they do not suffer any clinically meaningful changes in health -
related quality of life.